Streetbeat News

Analyst Ratings

APLS

Apellis Pharmaceuticals Inc's stock is trading lower following a report by Citron Research that casts doubt on the company's prospects and the safety of its recently approved treatment for Geographic Atrophy, Syfovre. The report anticipates an FDA warning letter and criticizes the lack of transparency surrounding the drug's approval process and side effect reports. Apellis is under scrutiny for alleged underreporting of retinal vasculitis cases associated with Syfovre use.

Portfolio Pulse from Vandana Singh

November 06, 2023 | 7:12 pm

ENB

Over the past 3 months, 3 analysts have published their opinion on Enbridge (NYSE:ENB) stock. The company has an average price target of $55.0, a decrease of 4.06% from the previous average price target of $57.33. The ratings include 1 somewhat bullish, 2 indifferent, and no bearish opinions.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

STGW

Stagwell (NASDAQ:STGW) has received 11 bullish ratings and 3 indifferent ratings from 14 analysts over the last quarter. The average price target is $8.0, implying an upside from the current price of $4.74. However, this average has decreased by 21.72% from the previous average price target of $10.22.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

PLYM

In the last quarter, Plymouth Industrial REIT (NYSE:PLYM) received four bullish analyst ratings. The company has an average 12-month price target of $25.75, with a high of $27.00 and a low of $24.00. The average price target has increased by 0.31% over the past month.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

FTNT

In the last quarter, 24 analysts have provided ratings for Fortinet (NASDAQ:FTNT), with 9 being bullish, 3 somewhat bullish, and 12 indifferent. The company has an average 12-month price target of $64.92, a decrease of 12.4% from the previous average price target of $74.11.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

ORLY

O'Reilly Automotive's (NYSE:ORLY) short percent of float has risen 21.88% since its last report, with 1.38 million shares sold short, which is 2.34% of all regular shares available for trading. It would take traders 3.95 days to cover their short positions on average. The company's short interest is less than its peer group average of 12.49%.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

BN

Brookfield's (NYSE:BN) short percent of float has risen 13.51% since its last report, with 18.67 million shares sold short, which is 1.26% of all regular shares available for trading. This increase in short interest can act as an indicator of market sentiment towards a particular stock. However, compared to its peers, Brookfield has less short interest as a percentage of float, which is 2.95% on average.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

SO

Southern's (NYSE:SO) short percent of float has risen 8.0% since its last report, with 11.74 million shares sold short, which is 1.08% of all regular shares available for trading. It would take traders 2.28 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. Southern's peer group average for short interest as a percentage of float is 2.21%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

RVNC

Revance Therapeutics (NASDAQ:RVNC) has received various analyst ratings in the last quarter, with the majority being bullish. The average price target from these analysts is $32.46, which is significantly higher than the current price of $9.35. However, this average represents a 17.19% decrease from the previous average price target of $39.20.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm

SBOW

Over the past 3 months, 4 analysts have published their opinion on SilverBow Resources (NYSE:SBOW) stock, with 2 being bullish and 2 somewhat bullish. The company has an average 12-month price target of $54.75, which has increased by 7.88% over the past month.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 7:00 pm